Purpose of the development: New compound may be used as an anticoagulant and antigipoksichniogo funds during hypoxia of various etiologies (heart attack, stroke, shock, pneumonia, etc.), it is a stimulant of efficiency, but also has antioxidant and immunomodulatory effects, no adverse effects on various indicators of homeostasis.

Recommended application field: Medicine and Pharmaceuticals.

Advantages over analogues: No structural analogues. As the use of anticoagulants heparin, as antihypoxants - piracetam, gutimin, bemitil, hydroxybutyrate, but they do not meet the requirements of modern medicine.

The development stage readiness: The working documentation is developed

Technical and economic effect: Based on the availability of the starting reagents developed drug production seems profitable. The need for such a large specimen, both for patients and for healthy people.

Description of the development:
()
Izotiorbamin - 2 - (b-diethylamino) ethylmercapto-5-isopropyl-3,4-dihydropyrimidin-6-ol-4-one hydrochloride - original preparation, obtained by alkylation of 5-izopropiltiobarbiturovoy b-diethylaminoethyl acid under alkaline conditions. Developed experimental-industrial regulations on substance izotiorbamina. Available results are implemented in the educational and scientific process.

Information about newness of the development:
there are Ukrainian patents -- 1 items

corresponds technical description
Ready for implementation

Possibility of transfer abroad:
Licence's sale
Licence's sale
Technological document's sale
Combinated reduction to industrial level

Photo

Country Ukraine

For additional information turn to:
E-mail: gal@uintei.kiev.ua